Your browser doesn't support javascript.
loading
Non-covalent TMPRSS2 inhibitors identified from virtual screening
Xin Hu; Jonathan H Shrimp; Hui Guo; Miao Xu; Catherine Z. Chen; Wei Zhu; Alexey V. Zakharov; Sankalp Jain; Paul Shinn; Anton Simeonov; Matthew Hall; Min Shen.
Afiliação
  • Xin Hu; NIH/NCATS
  • Jonathan H Shrimp; National Institutes of Health
  • Hui Guo; NIH
  • Miao Xu; NIH/NCATS
  • Catherine Z. Chen; NIH/NCATS
  • Wei Zhu; NIH/NCATS
  • Alexey V. Zakharov; National Center for Advancing Translational Sciences
  • Sankalp Jain; NIH
  • Paul Shinn; NIH
  • Anton Simeonov; NIH
  • Matthew Hall; NCATS
  • Min Shen; NIH
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-424413
ABSTRACT
The SARS-CoV-2 pandemic has prompted researchers to pivot their efforts to finding antiviral compounds and vaccines. In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral life cycle by cleaving the spike protein to initiate membrane fusion. TMPRSS2 is an attractive target and has received attention for the development of drugs against SARS and MERS. Starting with comparative structural modeling and binding model analysis, we developed an efficient pharmacophore-based approach and applied a large-scale in silico database screening for small molecule inhibitors against TMPRSS2. The hits were evaluated in the TMPRSS2 biochemical assay and the SARS-CoV-2 pseudotyped particle (PP) entry assay. A number of novel inhibitors were identified, providing starting points for further development of drug candidates for the treatment of COVID-19.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Experimental_studies Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Experimental_studies Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...